



29-04

IFW

PTO/SB/21 (04-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

| | | |
|---|------------------------|-----------------------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | Application Number | 10/800,197 |
| | Filing Date | March 12, 2004 |
| | First Named Inventor | Phillip A. Morton |
| | Art Unit | 1645 |
| | Examiner Name | Unknown |
| Total Number of Pages in This Submission | Attorney Docket Number | 01343/1/US (6794-000145/US) |

ENCLOSURES (check all that apply)

| | | |
|--|--|--|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form HDP-1449; Cited References; Return Receipt Postcard |
| <div>Remarks</div> | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | |
|-------------------------------|---|
| Firm or Individual name | James E. Davis, PTO Reg. No. 47,516 Harness, Dickey & Pierce, P.L.C. |
| Signature | |
| Date | July 27, 2004 |

CERTIFICATE OF TRANSMISSION/MAILING

| | | | |
|---|--------------------|---------------------------|-----------------|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. | | | |
| Typed or printed name | Peggy Marie Leslie | Express Mail Label No. | EV 298497295 US |
| Signature | | Date | July 27, 2004 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 298497295 US



Attorney Docket No: 01343/1/US
HDP Docket No: 6794-0000145/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Morton et al.
Serial No: 10/800,197
Filed: March 12, 2004
For: Antibodies to IGF-I Receptor For the Treatment of Cancers
Art Unit: 1645
Examiner: Unknown
Attorney Docket: 01343/1/US

July 27, 2004

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam/Sir:

In accordance with 37 CFR §1.97 and §1.98, and MPEP §609, and in compliance with the duty of disclosure set forth in 37 CFR §1.56 Applicants hereby submit the references cited on the attached Form PTO-1449 for consideration and entry in the above-referenced patent application.


Applicants submit this Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents Applicants are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104(a) and §1.106(b) and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.

Applicants believe that this Information Disclosure Statement is being submitted before the mailing of a first Office action on the merits and thus no fee is owed. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. 08-0750. In addition, if there is ever any other fee deficiency or overpayment

EV 298497295 US

under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

Respectfully submitted,




James E. Davis, PTO Reg. No. 47,516
Harness, Dickey & Pierce
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on July 27, 2004 with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.


Peggy Marie Leslie

JED/ECR



FORM PTO-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 5

ATTORNEY DOCKET NO.

01343/1/US

SERIAL No.

10/800,197

APPLICANT

Morton et al.

FILING DATE

March 12, 2004

GROUP

1645

FOREIGN PATENT DOCUMENTS

| Ref. Desig. | Examiner's Initials | Document Number | Date | Country | Class/ Subclass | Translation Yes | No |
|-------------|---------------------|-----------------|------------|---------|-----------------|-----------------|----|
| 1. | | WO 02/053596 | 07/11/2002 | PCT | C07K 16/28 | | |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

| Ref. Desig. | Examiner's Initials | |
|-------------|---------------------|--|
| 2. | | Rechler and Nissley, The Nature and Regulation of the Receptors for Insulin-Like Growth Factors, <i>Ann. Rev. Physiol.</i> , Vol. 47, pp. 425-42, 1985 |
| 3. | | Goldring and Goldring, Cytokines and Cell Growth Control, <i>Eukar. Gene Express.</i> , Vol. 1(4), pp. 301-326, 1991 |
| 4. | | Ullrich and Schlessinger, Signal Transduction by Receptors with Tyrosine Kinase Activity, <i>Cell</i> , Vol. 61, pp. 203-212, 1990 |
| 5. | | Ullrich et al., Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity, <i>EMBO J.</i> , Vol. 56, pp. 2503-2512, 1986 |
| 6. | | Massague and Czech, The Subunit Structures of Two Distinct Receptors for Insulin-like Growth Factors I and II and Their Relationship to the Insulin Receptor, <i>J. Biol. Chem.</i> , Vol. 257(9), pp. 5038-5045, 1982 |
| 7. | | Kato et al., Essential Role of Tyrosine Residues 1131, 1135, and 1136 of the Insulin-Like Growth Factor-I (IGF-I) Receptor in IGF-I Action, <i>Mol. Endocrinol.</i> , Vol. 8(1), pp. 40-50, 1994 |
| 8. | | Daughaday and Rotwein, Insulin-Like Growth Factors I and II. Peptide, Messenger, Ribonucleic Acid and Gene Structures, Serum, and Tissue Concentrations, <i>Endocrine Rev.</i> Vol. 10(1), pp. 68-91, 1989 |
| 9. | | Werner and LeRoith, The Role of Insulin-like Growth Factor System in Human Cancer, <i>Adv. Cancer Res.</i> , Vol. 68, pp. 183-223, 1996 |
| 10. | | Grimberg and Cohen, Role of Insulin-Like Growth Factors and Their Binding Proteins in Growth Control and Carcinogenesis, <i>J. Cell. Physiol.</i> , Vol. 183, pp. 1-9, 2000 |
| 11. | | Kaiser et al., Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer, <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 119, pp. 665-668, 1993 |
| 12. | | Moody and Cuttitta, Growth Factor and Peptide Receptors in Small Cell Lung Cancer, <i>Life Sciences</i> , Vol. 52, pp. 1161-1173, 1993 |

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 298497295 US

| | | |
|--|---------------------|------------|
| FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 2 of 5 | ATTORNEY DOCKET NO. | SERIAL NO. |
| | 01343/1/US | 10/800,197 |
| | APPLICANT | |
| | Morton et al. | |
| | FILING DATE | GROUP |
| | March 12, 2004 | 1645 |

| OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) | | |
|--|---------------------|---|
| Ref. Desig. | Examiner's Initials | |
| 13. | | Macaulay et al., Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells, <i>Cancer Res.</i> , Vol. 50, pp. 2511-2517, 1990 |
| 14. | | Pollak et al., Presence of Somatomedin Receptors on Primary Human Breast And Colon Carcinomas, <i>Cancer Lett.</i> , Vol. 38, pp. 223-230, 1987 |
| 15. | | Foekens et al., Prognostic Value of Receptors for Insulin-like Growth Factors 1, Somatostatin, and Epidermal Growth Factors in Human Breast Cancer, <i>Cancer Res.</i> , Vol. 49, pp. 7002-7009, 1989 |
| 16. | | Hellawell et al., Expression of the Type 1 Insulin-like Growth Factor Receptor Is Up-Regulated in Primary Prostate Cancer and Commonly Persist in Metastatic Disease, <i>Cancer Res.</i> , Vol. 62, pp. 2942-2950, 2002 |
| 17. | | Remacle-Bonnet et al., Expression of Type I, but not Type II Insulin-Like Growth Factor Receptor on Both Undifferentiated and Differentiated HT29 Human Colon Carcinoma Cell Line, <i>J Clin. Endocrinol. Metab.</i> , Vol. 75, pp. 609-616, 1992 |
| 18. | | Guo et al., Characterization of Insulinlike Growth Factor I Receptors in Human Colon Cancer, <i>Gastroenterol.</i> , Vol. 102, pp. 1101-1108, 1992 |
| 19. | | Soos et al., Receptors for insulin and insulin-like growth factor-I can form hybrid dimmers, <i>Biochem. J.</i> , Vol. 270, pp. 383-390, 1990 |
| 20. | | Baillyes et al., Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting, <i>Biochem. J.</i> , Vol. 327, pp. 209-215, 1997 |
| 21. | | Del Valle et al., Insulin-like Growth Factor I Receptor Activity in Human Medulloblastomas, <i>Clin. Cancer Res.</i> , Vol. 8, pp. 1822-1830, 2002 |
| 22. | | Resnik et al., Elevated Insulin-like Growth Factor I Receptor Autophosphorylation and Kinase Activity in Human Breast Cancer, <i>Cancer Res.</i> , Vol. 58, pp. 1159-1164, 1998 |
| 23. | | DiGiovanni et al., Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 97, pp. 3455-3460, 2000 |
| 24. | | Sandberg-Nordqvist et al., Characterization of Insulin-like Growth Factor 1 in Human Primary Brain Tumors, <i>Cancer Res.</i> , Vol. 53, pp. 2475-2478, 1993 |

| | |
|-----------|------------------|
| Examiner: | Date Considered: |
|-----------|------------------|

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|---------------------|------------|
| <p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>(Use several sheets if necessary)</p> <p>Sheet 3 of 5</p> | ATTORNEY DOCKET NO. | SERIAL NO. |
| | 01343/1/US | 10/800,197 |
| | APPLICANT | |
| | Morton et al. | |
| | FILING DATE | GROUP |
| | March 12, 2004 | 1645 |

| OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) | | |
|--|---------------------|---|
| Ref. Desig. | Examiner's Initials | |
| 25. | | Butler et al., Stimulation of Tumor Growth by Recombinant Human Insulin-like Growth Factor-I (IGF-I) Is Dependent on the Dose and the Level of the IGF-I Receptor Expression, <i>Cancer Res.</i> , Vol. 58, pp. 3021-3027, 1998 |
| 26. | | Rosen and Pollak, Circulating IGF-I: New Perspectives for a New Century, <i>Trends Endocrinol. Metab.</i> , Vol. 10, pp. 136-141, 1999 |
| 27. | | Nakanishi et al., Insulin-like Growth Factor-I Can Mediate Autocrine Proliferation of Human Small Cell Lung Cancer Cell Lines In Vitro, <i>J Clin. Invest.</i> , Vol. 82, pp. 354-359, 1988 |
| 28. | | Freed and Herington, Insulin-like growth factor-I and its autocrine role in growth of MCF-7 human breast cancer cells in culture, <i>J. Mol. Endocrinol.</i> Vol. 3, pp. 509-514, 1989 |
| 29. | | LeRoith et al., Molecular and Cellular Aspects of the Insulin-Like Growth Factor I Receptor, <i>Endocrine Revs.</i> , Vol. 16, pp. 143-163, 1995 |
| 30. | | Yee et al., Analysis of Insulin-Like Growth Factor I Gene Expression in Malignancy: Evidence for a Paracrine Role in Human Breast Cancer, <i>Mol. Endocrinol.</i> , Vol. 3, pp. 509-514, 1989 |
| 31. | | Weber et al., Overexpression of the Insulin-Like Growth Factor I Receptor in Human Colon Carcinomas, <i>Cancer</i> , Vol. 95, pp. 2086-2095, 2002 |
| 32. | | Hassan and Macaulay, The insulin-like growth factor system as a therapeutic target in colorectal cancer, <i>Anal. of Oncology</i> , Vol. 13, pp. 349-356, 2002 |
| 33. | | Wraight et al., Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides, <i>Nat. Biotech.</i> , Vol. 18, pp. 521-526, 2000 |
| 34. | | Pietrzowski et al., Constitutive Expression of Insulin-like Growth Factor 1 and Insulin-like Growth Factor 1 Receptor Abrogates All Requirements for Exogenous Growth Factors, <i>Cell Growth & Diff.</i> , Vol. 3, pp. 199-205, 1992 |
| 35. | | Pietrzowski et al., Roles of Insulinlike Growth Factor 1 (IGF-1) and the IGF-1 Receptor in Epidermal Growth Factor-Stimulated Growth of 3T3 Cells, <i>Mol. Cell. Biol.</i> , Vol. 12, pp. 3883-3889, 1992 |
| 36. | | Trojan et al., Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNA, <i>Science</i> , Vole. 259, pp. 94-97, 1992 |
| 37. | | Kull et al., Monoclonal Antibodies to Receptors for Insulin and Somatomedin-C, <i>J. Biol. Chem.</i> , Vol. 258, pp. 6561-6566, 1983 |

| | |
|-----------|------------------|
| Examiner: | Date Considered: |
|-----------|------------------|

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|---------------------|------------|
| <p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>(Use several sheets if necessary)</p> <p>Sheet 4 of 5</p> | ATTORNEY DOCKET NO. | SERIAL NO. |
| | 01343/1/US | 10/800,197 |
| | APPLICANT | |
| | Morton et al. | |
| | FILING DATE | GROUP |
| | March 12, 2004 | 1645 |

| OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) | | |
|--|---------------------|---|
| Ref. Desig. | Examiner's Initials | |
| 38. | | Arteaga, Interference of the IGF system as a strategy to inhibit breast cancer growth, <i>Breast Cancer Res. Treat.</i> , Vol. 22, pp. 101-106, 1992 |
| 39. | | Rohlik et al., An Antibody To The Receptor For Insulin-Like Growth Factor I Inhibits the Growth of MCF-7 Cells In Tissue Culture, <i>Biochem. Biophys. Res. Commun.</i> , Vol. 149, pp. 276-281, 1987 |
| 40. | | Arteaga et al., Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice, <i>J. Clin. Invest.</i> , Vol. 84, pp. 1418-1423, 1989 |
| 41. | | Kalebic et al., <i>In Vivo</i> Treatment with Antibody against IGF-1 Receptor Suppresses Growth of Human Rhabdomyosarcoma and Down-Regulates p34 ^{cdc2} , <i>Cancer Res.</i> , Vol. 54, pp. 5531-5534, 1994 |
| 42. | | Li et al., Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth, <i>Cancer Immunol. Immunother.</i> , Vol. 49, pp. 243-252, 2000 |
| 43. | | Sachdev et al., A Chimeric Humanized Single-Chain Antibody against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-I, <i>Cancer Res.</i> , Vol. 63, pp. 627-635, 2003 |
| 44. | | Prager et al., Dominant negative inhibition of tumorigenesis <i>in vivo</i> by human insulin-like growth factor I receptor mutant, <i>Proc. Natl. Acad. Sci USA</i> , Vol. 91, pp. 2181-2185, 1994 |
| 45. | | Li et al., Mitogenicity and Transforming Activity of the Insulin-like Growth Factor-I Receptor with Mutations in the Tyrosine Kinase Domain, <i>J. Biol. Chem.</i> , Vol. 269, pp. 32558-32564, 1994 |
| 46. | | Jiang et al., Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor, <i>Oncogene</i> , Vol. 18, pp. 6071-6077, 1999 |
| 47. | | Williams, Programmed Cell Death: Apoptosis and Oncogenesis, <i>Cell</i> , Vol. 65, pp. 1097-1098, 1991 |
| 48. | | Lane, A death in the life of p53, <i>Nature</i> , Vol. 362, pp. 786-787, 1993 |
| 49. | | Rodriguez-Tarduchy et al., Insulin-Like Growth Factor-I Inhibits Apoptosis in IL-3-Dependent Hemopoietic Cells, <i>J. Immunol.</i> , Vol. 149, pp. 535-540, 1992 |
| 50. | | Harrington et al., c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines, <i>EMBO J.</i> , Vol. 13, pp. 3286-3295, 1994 |

| | |
|-----------|------------------|
| Examiner: | Date Considered: |
|-----------|------------------|

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|---------------------|------------|
| <p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>(Use several sheets if necessary)</p> <p>Sheet 5 of 5</p> | ATTORNEY DOCKET NO. | SERIAL NO. |
| | 01343/1/US | 10/800,197 |
| | APPLICANT | |
| | Morton et al. | |
| | FILING DATE | GROUP |
| | March 12, 2004 | 1645 |

| OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) | | |
|--|---------------------|---|
| Ref. Desig. | Examiner's Initials | |
| 51. | | McDonnell et al., bcl-2-Immunoglobulin Transgenic Mice Demonstrate Extended B Cell Survival and Follicular Lymphoproliferation, <i>Cell</i> , Vol. 57, pp. 79-88, 1989 |
| 52. | | Hockenberry et al., Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death, <i>Nature</i> , Vol. 348, pp. 334-336, 1990 |
| 53. | | Resnicoff et al., Correlation between Apoptosis, Tumorigenesis, and Levels of Insulin-like Growth Factor I Receptors, <i>Cancer Res.</i> , Vol. 55, pp. 3739-3741, 1995 |
| 54. | | Sell et al., Insulin-like Growth Factor I (IGF-I) and the IGF-I Receptor Prevent Etoposide-induced Apoptosis, <i>Cancer Res.</i> , Vol. 55, pp. 303-306, 1995 |
| 55. | | Resnicoff et al., The Insulin-like Growth Factor I Receptor Protects Tumor Cells from Apoptosis <i>in Vivo</i> , <i>Cancer Res.</i> , Vol. 55, pp. 2463-2469, 1995 |
| 56. | | D'Ambrosio et al., A Soluble Insulin-like Growth Factor I Receptor That Induces Apoptosis of Tumor Cells <i>in Vivo</i> and Inhibits Tumorigenesis, <i>Cancer Res.</i> , Vol. 56, pp. 4013-4020, 1996 |
| 57. | | Thompson et al., Low Prevalence of Autoantibodies to the Insulin-like Growth Factor I Receptor in Children with Short Stature, <i>Pediat. Res.</i> , Vol. 32, pp. 455-459, 1988 |
| 58. | | Tappy et al., Antibodies to Insulin-Like Growth Factor I Receptors in Diabetes and Other Disorders, <i>Diabetes</i> , Vol. 37, pp. 1708-1714, 1988 |
| 59. | | Weightman et al., Autoantibodies to IGF-1 Binding Sites in Thyroid Associated Ophthalmopathy, <i>Autoimmunity</i> , Vol. 16, pp. 251-257, 1993 |
| 60. | | Drexhage and Wulffraat, Endocrine autoimmune diseases, <i>Nether. J. of Med.</i> , Vol. 45, pp. 285-293, 1994 |
| 61. | | Xiong et al., Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor, <i>Proc. Natl Acad. Sci USA</i> , Vol. 89, pp. 5356-5360, 1992 |
| 62. | | Macaulay, Insulin-like growth factors and cancer, <i>Br. J. Cancer</i> , Vol. 65, pp. 311-320, 1992 |

| | |
|-----------|------------------|
| Examiner: | Date Considered: |
|-----------|------------------|

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.